Expert Panel Approves Post-Marketing Surveillance Study of Eculizumab (Soliris) by AstraZeneca in India
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted approval to AstraZeneca Pharma India Ltd to conduct a Post Marketing Surveillance (PMS) study for its monoclonal antibody drug Eculizumab (Soliris) in India.
As per the official minutes, “The firm presented the proposal to conduct the Post Marketing Surveillance Study (PMS) in India for Eculizumab concentrate for solution for infusion 300 mg (10mg/ml) (Soliris) titled ‘A Prospective, Observational, Multicenter, Post Marketing Surveillance Study to assess safety of Eculizumab in Indian patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)’ vide study code D7414R00002 Version 1.0 dated 09.04.2025 as per the condition of Marketing Authorization approval.”
Following detailed deliberation during the SEC (Hematology) meeting held on 28th May 2025, the committee stated:
“After detailed deliberation, the committee recommended for grant of permission to conduct the Post Marketing Surveillance Study (PMS) as per the protocol presented by the firm.”
Eculizumab is a humanized monoclonal antibody that targets complement protein C5. By binding to this protein, it prevents activation of the terminal complement cascade, a critical mechanism in several rare and severe autoimmune diseases. The drug is approved for treating Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS).
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.